The 13 TNF inhibitor research showed no considerable heterogeneity (I2 = 42 , p = 0.06). The
The 13 TNF inhibitor studies showed no considerable heterogeneity (I2 = 42 , p = 0.06). The borderline heterogeneity was due to two golimumab research (GoBefore, GoForward) . The exclusion…